# US 2021/0094979 A1 · Pharmaceutical co-crystal composition and use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0094979 A1
- Document ID: US20210094979A1
- Status: Published application
- Kind: A1
- Application number: 17/122,380
- Filed: 2020-12-15
- Published: 2021-04-01
- Earliest claimed: 2015-06-25
- Assignees: Syn-Nat Products Enterprise LLC
- Applicants: Syn-Nat Products Enterprise LLC
- Inventors: Xiaozhong LIU
- Web page: https://patentgrep.com/patent/US20210094979A1

## CPC

- C07F 15/0093: {without a metal-carbon linkage}
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/08: Solutions {(composition of solutions A61K47/00)}
- A61K 31/282: Platinum compounds
- A61K 33/243: Platinum; Compounds thereof
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 47/26: Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A61K 47/542: {Carboxylic acids, e.g. a fatty acid or an amino acid}
- A61P 35/00: Antineoplastic agents
- C07C 61/04: Saturated compounds having a carboxyl group bound to a three or four-membered ring
- C07C 61/06: Saturated compounds having a carboxyl group bound to a five-membered ring
- C07B 2200/13: Crystalline forms, e.g. polymorphs
- C07F: ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM (metal-containing porphyrins C07D487/22)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07B: GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR (preparation of carboxylic acid esters by telomerisation C07C67/47; telomerisation C08F)

## Abstract

The current invention relates to series of co-crystals of platinum analogues and their pharmaceutical use. The co-crystals of the subject invention may be used in the treatment or prevention of cancers and virus infections.

## Claims

### Claim at position 1

1-31. (canceled)

### Claim 32

A co-crystal comprising a platinum analogue of formula Pt-02:
and a diacid selected from the group consisting of:

### Claim 33 (depends on 32)

The co-crystal of claim 32, wherein the diacid is selected from the group consisting of formulas CF-01, CF-02, and CF-08.

### Claim 34 (depends on 32)

The co-crystal of claim 32, which is
a co-crystal comprising the platinum analogue of formula Pt-02 and the diacid of formula CF-02 and having an XRPD pattern comprising peaks at diffraction angles 2-Theta of 7.3°, 9.4°, 10.1°, 12.5°, 13.6° and 23.4°±0.2, an XRPD pattern comprising peaks as set forth in FIG. 14 or an XRPD pattern substantially similar to the pattern as set forth in FIG. 14; or
a co-crystal comprising the platinum analogue of formula Pt-02 and the diacid of formula CF-08 and having an XRPD pattern comprising peaks at diffraction angles 2-Theta of 7.9°, 11.9°, 14.5°, 15.8°, 17.0°, 17.4° and 17.8°±0.2, an XRPD pattern comprising peaks as set forth in FIG. 17 or an XRPD pattern substantially similar to the pattern as set forth in FIG. 17.

### Claim 35 (depends on 32)

The co-crystal of claim 32, which is a co-crystal comprising the platinum analogue of formula Pt-02 and the diacid of formula CF-01 and having an XRPD pattern comprising peaks at diffraction angles 2-Theta of 7.1°, 9.2°, and 10.1°±0.2.

### Claim 36 (depends on 32)

The co-crystal of claim 32, which is a co-crystal comprising the platinum analogue of formula Pt-02 and the diacid of formula CF-08 and having an XRPD pattern comprising peaks as set forth in FIG. 15 or an XRPD pattern substantially similar to the pattern as set forth in FIG. 15.

### Claim 37 (depends on 32)

A pharmaceutical composition comprising the co-crystal of claim 32.

### Claim 38 (depends on 34)

A pharmaceutical composition comprising the co-crystal of claim 34.

### Claim 39 (depends on 35)

A pharmaceutical composition comprising the co-crystal of claim 35.

### Claim 40 (depends on 36)

A pharmaceutical composition comprising the co-crystal of claim 36.

### Claim 41 (depends on 37)

The pharmaceutical composition of claim 37, which is an aqueous composition, wherein the co-crystal is dissolved or dispersed in a pharmaceutically acceptable carrier or aqueous media.

### Claim 42 (depends on 37)

The pharmaceutical composition of claim 37, further comprising a therapeutic agent or adjuvant therapy agent selected from the group consisting of folic acid, coenzyme Q10, curcumin, glutathione (GSH), aloe vera, oryzanol, 5-fluorouracil, and bortezomib.

### Claim 43 (depends on 37)

A method of treating cancer in a subject in need thereof, comprising administering to the subject the pharmaceutical composition of claim 37, wherein the co-crystal is in a therapeutically effective amount.

### Claim 44 (depends on 39)

A method of treating cancer in a subject in need thereof, comprising administering to the subject the pharmaceutical composition of claim 39, wherein the co-crystal is in a therapeutically effective amount.

### Claim 45 (depends on 40)

A method of treating cancer in a subject in need thereof, comprising administering to the subject the pharmaceutical composition of claim 40, wherein the co-crystal is in a therapeutically effective amount.

### Claim 46 (depends on 43)

The method of claim 43, wherein the cancer is prostate cancer, colorectal cancer, or renal adenocarcinoma.

### Claim 47

A method of preparing a co-crystal comprising:
a) mixing a platinum analogue and a diacid in water,
b) slurrying or stirring the mixture from step a) for a sufficient period of time to form a co-crystal of the platinum analog and the diacid; and optionally
c) isolating the co-crystal,
wherein the platinum analog is a platinum analogue of formula Pt-02:
and the diacid is selected from the group consisting of:

### Claim 48 (depends on 47)

The method of claim 47, wherein the molar ratio of the platinum analogue to the diacid is in range of 1:0.1 to 1:20.

### Claim 49 (depends on 48)

The method of claim 48, wherein the diacid is CF-01.

### Claim 50 (depends on 47)

The co-crystal produced by the method of claim 47.

### Claim 51 (depends on 49)

The co-crystal produced by the method of claim 49.
